Author: Abers, Michael S.; Delmonte, Ottavia M.; Ricotta, Emily E.; Fintzi, Jonathan; Fink, Danielle L.; de Jesus, Adriana A. Almeida; Zarember, Kol A.; Alehashemi, Sara; Oikonomou, Vasileios; Desai, Jigar V.; Canna, Scott W.; Shakoory, Bita; Dobbs, Kerry; Imberti, Luisa; Sottini, Alessandra; Quiros-Roldan, Eugenia; Castelli, Francesco; Rossi, Camillo; Brugnoni, Duilio; Biondi, Andrea; Bettini, Laura Rachele; D’Angio’, Mariella; Bonfanti, Paolo; Castagnoli, Riccardo; Montagna, Daniela; Licari, Amelia; Marseglia, Gian Luigi; Gliniewicz, Emily F.; Shaw, Elana; Kahle, Dana E.; Rastegar, Andre T.; Stack, Michael; Myint-Hpu, Katherine; Levinson, Susan L.; DiNubile, Mark J.; Chertow, Daniel W.; Burbelo, Peter D.; Cohen, Jeffrey I.; Calvo, Katherine R.; Tsang, John S.; Su, Helen C.; Gallin, John I.; Kuhns, Douglas B.; Goldbach-Mansky, Raphaela; Lionakis, Michail S.; Notarangelo, Luigi D.
Title: An immune-based biomarker signature is associated with mortality in COVID-19 patients Cord-id: k75fiou6 Document date: 2021_1_11
ID: k75fiou6
Snippet: Immune and inflammatory responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contribute to disease severity of coronavirus disease 2019 (COVID-19). However, the utility of specific immune-based biomarkers to predict clinical outcome remains elusive. Here, we analyzed levels of 66 soluble biomarkers in 175 Italian patients with COVID-19 ranging from mild/moderate to critical severity and assessed type I IFN–, type II IFN–, and NF-κB–dependent whole-blood transcriptiona
Document: Immune and inflammatory responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contribute to disease severity of coronavirus disease 2019 (COVID-19). However, the utility of specific immune-based biomarkers to predict clinical outcome remains elusive. Here, we analyzed levels of 66 soluble biomarkers in 175 Italian patients with COVID-19 ranging from mild/moderate to critical severity and assessed type I IFN–, type II IFN–, and NF-κB–dependent whole-blood transcriptional signatures. A broad inflammatory signature was observed, implicating activation of various immune and nonhematopoietic cell subsets. Discordance between IFN-α2a protein and IFNA2 transcript levels in blood suggests that type I IFNs during COVID-19 may be primarily produced by tissue-resident cells. Multivariable analysis of patients’ first samples revealed 12 biomarkers (CCL2, IL-15, soluble ST2 [sST2], NGAL, sTNFRSF1A, ferritin, IL-6, S100A9, MMP-9, IL-2, sVEGFR1, IL-10) that when increased were independently associated with mortality. Multivariate analyses of longitudinal biomarker trajectories identified 8 of the aforementioned biomarkers (IL-15, IL-2, NGAL, CCL2, MMP-9, sTNFRSF1A, sST2, IL-10) and 2 additional biomarkers (lactoferrin, CXCL9) that were substantially associated with mortality when increased, while IL-1α was associated with mortality when decreased. Among these, sST2, sTNFRSF1A, IL-10, and IL-15 were consistently higher throughout the hospitalization in patients who died versus those who recovered, suggesting that these biomarkers may provide an early warning of eventual disease outcome.
Search related documents:
Co phrase search for related documents- absolute lymphocyte count and admission day: 1, 2, 3
- absolute lymphocyte count and longitudinal biomarker: 1
- absolute lymphocyte count and lung function: 1, 2, 3, 4
- absolute lymphocyte count and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
Co phrase search for related documents, hyperlinks ordered by date